Keros Therapeutics Q2 2026 net loss $28.7M; initiates Phase 2 DMD trial for rinvatercept

Keros Therapeutics, Inc.

Net loss of $28.7M in Q2 2026 vs $30.7M in Q2 2025; R&D expenses down to $22.3M from $43.5M.
Cash and cash equivalents $257.6M as of June 30, 2026; expected to fund operations into first half 2028.
Initiated Phase 2 clinical trial of rinvatercept in Duchenne muscular dystrophy; initial data expected first half 2027.
General and administrative expenses decreased to $8.6M from $14.5M due to restructuring and lower professional fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.